Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): Methodological considerations

Journal of Clinical Epidemiology

Volumn 54, Issue 5, 2001, Pages 518-524

  Souverein, P C ^a   Herings, R M C ^a   De La Rosette, J J M C H ^b   Man In 'T Veld, A J ^c   Farmer, R D T ^d   Leufkens, H G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Benign prostatic hyperplasia; Bias; Cardiovascular disease; Co occurrence; Database research; Epidemiologic methods

Indexed keywords

ALFUZOSIN; CARDIOVASCULAR AGENT; FINASTERIDE; TAMSULOSIN; TERAZOSIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DATA BASE; EPIDEMIOLOGY; HUMAN; MALE; METHODOLOGY; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; BIAS (EPIDEMIOLOGY); CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; MORBIDITY; NETHERLANDS; PRAZOSIN; PROGNOSIS; PROSTATIC HYPERPLASIA; QUINAZOLINES; RESEARCH DESIGN; RISK FACTORS; SULFONAMIDES; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0035038139     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(00)00327-9     Document Type: Article

References (31)

1. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists
2. The risk of myocardial infarction associated with antihypertensive drug therapies
3. Third generation oral contraceptives and risk of venous thromboembolic disorders; an international case-control study
4. Calcium channel blockers and the risk of cancer
5. Confounding and indication for treatment in evaluation of drug treatment for hypertension
6. Channeling bias in the interpretation of drug effects
7. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias
8. Oral contraceptive switching patterns in the United Kingdom; an important potential confounding variable in studies of venous thromboembolism
9. Selection of controls in database case-control studies; glucocorticoids and the risk of glaucoma
10. The development of human benign prostatic hyperplasia with age
11. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist; a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH)
12. Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia
13. Pharmacotherapy for benign prostatic hyperplasia-the potential for alpha 1-adrenoceptor subtype-specific blockade
14. Overview of alpha-blocker therapy for benign prostatic hyperplasia
15. Meta-analysis of randomized clinical trials of finasteride
16. Drug treatment of hypertension in the elderly; the role of alpha-adrenoceptor blockade
17. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia; rationale and clinical experience
18. Doxazosin; a new approach to hypertension and benign prostatic hyperplasia
19. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension
20. Drug-induced chest pain and myocardial infarction. Reports to a national centre and review of the literature
21. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme
22. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life
23. Automated record linkage and other approaches to pharmacoepidemiology in The Netherlands
24. A chronic disease score from automated pharmacy data
25. Incidence of myocardial infarction in elderly men being treated with antihypertensive drugs; population based cohort study
26. Treatment choice for benign prostatic hyperplasia; a matter of urologist preference?
27. Prevalence and detection of micturition problems among 2,734 elderly men
28. Prostate symptoms in general practice; seriousness and inconvenience
29. Natural history of benign prostatic hyperplasia; appropriate case definition and estimation of its prevalence in the community
30. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners; 1-year results
31. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms; does co-morbidity alter tolerability?